NovImmune has currently seven promising monoclonal antibodies for the treatment of immune-related disorders in its pipeline with a balance of clinical and preclinical compounds. The most advanced is in clinical development phase II.
Each product, driven by its mechanism of action, has the potential to ultimately become a medicine for multiple diseases. Our lead product, NI-0401/anti-CD3 is already explored in Crohn’s disease, Type 1 diabetes, and transplantation.
Find out more about each of our products by clicking on it in the image below.
| Product | Indication | Research | Pre-Clinical | Phase I | Phase II | Phase III | |
| NI-0401/α-CD3 | T1D |  |
|||||
| NI-0401/α-CD3 | CD | |
|||||
| NI-0401/α-CD3 | Tx | |
|||||
| NI-0801/α-IP-10 | AIID | |
|||||
| NI-0501/α-IFNγ | AIID | |
|||||
| NI-0701/α-RANTES | AIID | |
|||||
| NI-1401/α-IL-17 | AIID | |
|||||
| NI-0101/α-TLR4 | AIID | |
|||||
| NI-1201/α-IL-6Rc | AIID | |
|||||
Acronyms:
T1D: Type 1 Diabetes
CD: Crohn's Disease
TX: Transplantation
AIID: Auto-Immune and Inflammatory Diseaseas